Inflammatory demyelinating polyradiculoneuropathy

Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, and Axonal Degeneration and Regeneration... 

Krendel DA, Parks HP, Anthony DC, St Clair MB, Graham DG (1989) Sural nerve biopsy in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 12 257-264. 

Figure 20.1. Hypothetical scheme of the immune response in acute inflammatory demyelinating polyradiculoneuropathy (AIDP) Inflammatory cells migrate from the systemic immune compartment through the damaged blood-nerve barrier into the endoneurium. Inflammatory infiltrates, which contain T-lymphocytes and macrophages cause marked segmental demyelination and secondary axonal degeneration (B B-cell T T-cell M4> Macrophage).

AID AIDP AIDS AIF AIRE AIS AES AMAN AMN AMPA AMSAN activation-induced (cytidine) deaminase acute inflammatory demyelinating polyradiculoneuropathy acquired immunodeficiency syndrome apoptosis inducing factor autoimmune regulator anterior chamber associated immune deviation (ACAID)-inducing signal amyotrophic lateral sclerosis acute motor axonal neuropathy adrenomyeloneuropathy a-amino-3 -hydroxy-5-methylisoxazole- 4-propionic acid acute motor-sensory axonal neuropathy... 

Kolkin S, Nahman NS, Jr., Mendell JR. Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987 37 147-149. 

Observational studies In an observational study in 51 patients with primary immunodeficiencies with 642 infusions, drug-related adverse reactions occurred during six infusions in four patients none was serious [51 ]. In another study in 46 patients with primary immunodeficiency, 20% of the 601 infusions were associated with treatment-related adverse events, none of which was serious. Of the treatment-related adverse events, 59% were categorized as mild, 36% as moderate, and 5% as severe most were transient [44. In a safety study in 208 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 113 patients were exposed to 1096 infusions of intravenous immunoglobulin 55% had drug-related adverse events, an adverse event rate of 18 per 100 infusions, with five serious adverse reactions during the 1-year study [45. ... 

Donofrio PD, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Hughes R, Latov N, Merkies I, van Doom P. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010 67(9) 1082-8. 

Nervous system Infusion-related headache affected more than 50% of treated individuals in a cohort of patients with multiple sclerosis [138 ]. Anxiety, syncope, vertigo, dizziness, tremor, paresthesia, and hypesthe-sia are common undesirable reactions during treatment or within 30 days after the completion of treatment with alemtuzumab. Guil-lain-Barre syndrome and its chronic form, chronic inflammatory demyelinating polyradiculoneuropathy, have also been reported. 

---